Pacira Pharma (PCRX): Cutting Estimates - Jefferies

September 26, 2016 7:09 AM EDT
Get Alerts PCRX Hot Sheet
Price: $40.95 --0%

Rating Summary:
    11 Buy, 6 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 28 | Down: 28 | New: 23
Trade PCRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, David Steinberg, reiterated Buy rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) but cut his price target to $60.00 from $74.00. He attended the AAOMS meeting late last week and came away encouraged about the outlook for the use of Exparel in the oral surgery market but based on the monthly Symphony health data, Exparel's near term growth is slower than expected.

Exparel was recently launched into the oral surgery market (35M annual procedures) representing a large opportunity. Presenting KOLs highlighted the key attributes of reducing severe post-op pain, pre-op anxiety, and postop narcotics, particularly in teenagers.

Q3 & Q4 Exparel revs drop by $3M each to $63M and $72M. For FY17 Exparel revs drop by 9% to $328M, still a significant reacceleration in growth of 24% Y/Y.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $36.86 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment